MedPath

Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer

Phase 3
Completed
Conditions
Breast Cancer
Registration Number
NCT00006459
Lead Sponsor
Eli Lilly and Company
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if paclitaxel is more effective with or without gemcitabine for advanced breast cancer.

PURPOSE: Randomized phase III trial to study the effectiveness of paclitaxel with or without gemcitabine in treating women who have advanced breast cancer.

Detailed Description

OBJECTIVES: I. Compare overall survival of patients with unresectable, locally recurrent, or metastatic breast cancer treated with paclitaxel with or without gemcitabine.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two treatment arms. Patients receive paclitaxel with or without gemcitabine. Treatment continues every 21 days in the absence of disease progression. Patients are followed every 2-4 months for 2 years after active treatment.

PROJECTED ACCRUAL: Not specified

National Cancer Institute (NCI) registered this trial with Eli Lilly as sponsor. NCI did not update the record when the trial completed. In June 2012, NCI transferred the trial to Lilly's clinicaltrials.gov account and Lilly updated the record with the trial completion date. This trial is not an applicable trial under Food and Drug Administration Amendments Act of 2007 (FDAAA).

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (31)

Comprehensive Cancer Institute of Huntsville

🇺🇸

Huntsville, Alabama, United States

Little Rock Hematology-Oncology Associates

🇺🇸

Little Rock, Arkansas, United States

Pacific Coast Hematology/Oncology Medical Group

🇺🇸

Fountain Valley, California, United States

Office of Alex J.P. Makalinao

🇺🇸

Los Angeles, California, United States

Hematology/Oncology Group

🇺🇸

Santa Rosa, California, United States

University of Colorado Cancer Center

🇺🇸

Denver, Colorado, United States

Danbury Internal Medicine

🇺🇸

Danbury, Connecticut, United States

Comprehensive Cancer Care Specialists of Boca Raton

🇺🇸

Boca Raton, Florida, United States

Mercy Hospital

🇺🇸

Miami, Florida, United States

Mountain States Tumor Institute

🇺🇸

Boise, Idaho, United States

Scroll for more (21 remaining)
Comprehensive Cancer Institute of Huntsville
🇺🇸Huntsville, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.